N on-small cell lung carcinoma (NSCLC) is the leading cause of cancer death worldwide, and the prognosis of NSCLC is still poor with a 5-year survival rate of less than 9% in the developing countries. 1 The current model by using information of clinical diagnosis, patient characteristics combined with pathology or stage, cannot accurately predict patient outcome. To further understand the biology of NSCLC development and prognosis, the information from single nucleotide polymorphisms (SNPs) in genes at molecular level is believed to help develop new effective treatment modalities and predict the prognosis.
Survivin, one member of inhibitors of apoptosis proteins gene family, is involved in regulation of apoptosis, cell cycle progression, and microtubule stability. [2] [3] [4] [5] Suvivin has also been observed to be selectively expressed in cancer cells but not in normal tissues. 5 The overexpression of survivin in human malignancies is considered to be an important indicator for advanced and chemoresistant disease, and correlates with more aggressive behavior and poorer prognosis, suggesting that survivin plays a critical role in carcinogenesis, prognostic, and therapeutic implications. 6 -10 SNPs of survivin may influence survivin expression, and further normal cell apoptosis, as well as aberrant cell cycle-dependent transcription. 11 Although several case-control studies have studied on the variants of survivin, [12] [13] [14] [15] more efforts should be performed to evaluate of the prognosis of survivin gene polymorphisms on NSCLC survival. We hypothesized that genetic variants in survivin gene might influence the expression of survivin, and result in chemoresistant and/or poor prognosis of NSCLC patients. To test the hypothesis, we selected 12 SNPs in survivin and evaluated the relationship between these SNPs and prognosis of NSCLC in a case-cohort study with 568 NSCLC patients in a Chinese population.
MATERIALS AND METHODS

Study Population
The patients' recruitment and subjects' characteristics and clinical features were described previously. 16 Briefly, a total of 568 NSCLC patients who had complete clinical and follow-up information and adequate DNA samples were prospectively recruited from the Cancer Hospital of Jiangsu Province and the First Affiliated Hospital of Nanjing Medical University, Nanjing, China, since July 2003 to April 2008 (see Supplementary Table, http://links.lww.com/JTO/A39).
The maximum duration of follow-up was 72 months (last follow-up date: July 2009). Our study was approved by the Institutional Review Board of Nanjing Medical University.
Selection of Gene Polymorphisms
Polymorphisms in survivin gene were selected by an approach combining both potentially functional SNPs and tagging SNPs. The details of selection strategy were presented elsewhere. 16 In brief, potentially functional polymorphisms were identified if they are located in the 5Ј-flanking regions, 5Ј-UTR, 3Ј-UTR and coding regions with amino acid changes, or have biologic significance according to the previous studies. Tagging SNPs (tSNP) were chosen from genotyped SNPs of CHB (Chinese Han Beijing), based on the HapMap database (minor allele frequency [MAF] Ն0.05, Hardy-Weinberg equilibrium p Ͼ 0.05 and call rate Ն90%), by Haploview 4.1 software. As a result, 12 SNPs (2 potentially functional SNPs and 10 tSNPs) in survivin gene were finally selected for genotyping and the details of the SNPs were shown in Table 1 .
Genotyping Assay
All 12 SNPs were genotyped by using the Illumina GoldenGate platform in Taizhou, Jiangsu province, China. The information on assay conditions, primers and probes is available on request. Quality control was described in details in our previous studies. 16, 17 One of the 12 SNPs was excluded from further analysis for the call rate less than 95% (rs2239680) ( Table 1) .
Statistical Analysis
Fisher's exact test was used to test the Hardy-Weinberg equilibrium. Survival time was calculated from the date of NSCLC diagnosis to the date of patient's dead or the last date of follow-up and median survival time (MST) was presented. If a patient was lost to follow-up or if the study ended before death, the outcome variable was flagged as censored. Kaplan 
RESULTS
Description of Patient Characteristics
Patients' characteristics and clinical features were described in Supplemental Table 1 (http://links.lww.com/JTO/A35). In short, among the 568 patients, 353 (62.2%) patients had an advanced disease with 221 (38.9%) diagnosed at stage III and 132 (23.2%) at stage IV. Most of the patients underwent special treatments, 368 (64.8%) underwent surgery and 462 (81.3%) received chemotherapy or radiotherapy. No significant differences were observed for the association between NSCLC-specific survival and patients' characteristics, except for clinical stage (Log-rank p Ͻ 0.001) and surgical operation (Log-rank p Ͻ 0.001). Patients of advanced stages or without surgery had obviously worse prognosis.
Single SNP Analysis
The effects of 11 survivin SNPs included in the final analysis on NSCLC survival were summarized in Table 2 . There were no significant associations for the 11 SNPs by performing Log-rank test in three genetic models, except for rs4789551 (Log-rank p for trend 0.045; GG versus AG/AA Log-rank p ϭ 0.013). However, when using multivariate Cox hazard proportion model, four SNPs (rs3764383, AG/GG versus AA, HR ϭ 0.78, 95% CI: 0.62-0.99, p ϭ 0.043; rs8073069, GG versus CC, HR ϭ 1.80, 95% CI: 1.17-2.78, 
Combined and Stratified Analysis
We also put the above four SNPs (rs3764383, rs8073069, rs4789551, and rs1042489) together to assess the combined effects on NSCLC survival (Table 2) . We found that the more unfavorable loci were carried, the shorter the MST was presented (p for trend ϭ 0.002). In the dichotomized analysis, high risk patients carrying 3 to 4 unfavorable loci had an MST of 13.90 months, whereas those low risk patients with 0 to 2 unfavorable loci had an MST of 25.90 months. In the further multivariate Cox model analysis, high risk group showed a significantly 1.84-fold (95% CI: 1.22-2.77) increased risk compared with low risk group. We further conducted stratified analyses to assess the dichotomized combined effects on NSCLC survival according to histology, stage (early stage, I-II; advanced stage, III-IV), surgical operation, and chemo-or radiotherapy status ( Table  3 ). The results showed that patients carrying unfavorable loci presented a slightly worse prognosis in the subgroups of female (HR: 3.41, 95% CI: 1.26 -9.25), advanced stage (HR: 2.35, 95% CI: 1.48 -3.73), ever smokers (HR: 1.94, 95% CI: 1.20 -3.14), adenocarcinoma (HR: 2.08, 95% CI: 1.24 -3.50), and without surgery (HR: 2.03, 95% CI: 1.09 -3.77). However, there was no significant heterogeneity between these subgroups. We then evaluated the multiplicative gene-gene/ gene-environment interactions between the SNPs rs3764383, rs8073069, rs4789551, rs1042489 and demographic/clinical factors by using multivariate Cox model. However, no statistical significant interactions were observed (data not shown). We also performed haplotype inference using the phase 2.1 based on the known genotypes of the four SNPs. However, no statistically significant association between the haplotypes of these four SNPs in survivin and lung cancer survival was evident (data not shown).
Subgroup Analysis among Patients with Only Chemotherapy
To evaluate the effects of the 11 SNPs on lung cancer survival among stage III to IV patients who treated with platinum-based agents and without surgical operation, we further performed a subgroup analysis. Interestingly, the G allele of rs8073069 had a significantly increased risk (p for trend: 0.007). In the multivariate analysis, significant risk effects of rs8073069 existed in all the genetic models (CG versus CC, HR: 1.42, 95% CI: 1.00 -2.02, p ϭ 0.049, GG versus CC, HR: 2.18, 95% CI: 1.13-4.23, p ϭ 0.021; CG/GG versus CC, HR: 1.50, 95% CI: 1.07-2.10, p ϭ 0.018; GG versus CG/CC, HR: 2.06, 95% CI: 1.10 -3.87, p ϭ 0.025; Table 4 ).
DISCUSSION
In this study among Chinese, we investigated the association between genetic polymorphisms of survivin gene and the prognosis of NSCLC. Among the 12 SNPs examined, 4 SNPs (rs3764383, rs8073069, rs4789551, and rs1042489) were associated with NSCLC prognosis but only rs8073069 remained in the final stepwise Cox regression model. In the further subgroup analysis, the patients carrying rs8073069 GG genotype had significantly shorter MST for those received only chemoagents treatment. Our findings suggest that polymorphisms in survivin gene might be important predictors for lung cancer prognosis and treatment outcome. Survivin, also known as birc5, is a 16.5-kd protein and the corresponding gene locates on human chromosome 17q25. Among proteins of the inhibitors of apoptosis protein family, survivin seems to be selectively expressed in transformed cells and in most human cancers, including NSCLC. 18 -22 Survivin has multiple functions including cytoprotection, inhibition of cell death, and cell-cycle regulation, especially at the mitotic process stage, and all of which are associated with cancer cell progression and eventually with patients' survival. Growing evidence was accumulated that the overexpression of survivin was associated with various human cancers, including NSCLC. [12] [13] [14] [15] [23] [24] [25] [26] [27] [28] [29] [30] [31] Recently, an in vitro study by Karna et al. 32 suggested that the decreased apoptosis caused by overexpression of survivin was the key point for EM011 mediating antiproliferative and proapoptotic activity in non-small cell A549 lung cancer cells. Krepela et al. 33 also found that the expression of the survivin gene could inhibit apoptosis and accelerate tumor cell proliferation to produce more aggressive carcinomas in lung cancer. Similary, a follow-up study by Chen et al. 34 found that patients with low survivin expression had significantly longer progression-free survival and overall survival in NSCLC. A metaanalysis showed that the expression level of survivin was correlated with the overall survival of NSCLC patients. 35 In our study, two SNPs located in the survivin promoter region (rs3764383, rs8073069), one SNP in 3Ј UTR (rs1042489), and one in intron (rs4789551) were significantly associated with a worse prognosis of NSCLC patients. Bioinformatics analysis of the 5Ј-flanking region of the survivin gene showed that there are several cell cycledependent elements (GGCGG), and one cell cycle homology region (ATTTGAA). 36, 37 These two SNPs (rs3764383, rs8073069) in the promoter region may depress survivin transcription by modifying the binding motif of the cycledependent elements/cycle homology region repressor. Therefore, survivin acts as an inhibitor of apoptosis that is essential for eliminating mutated or transformed cells from the body, and it is biologically plausible that subjects carrying a genotype with higher expression of survivin may have decreased apoptotic capacity to eliminate cells with DNA damage, and thus may have a shorter survival time and poorer prognosis. The effects of survivin were more notable in the subgroups of female, advanced stage, ever smokers through the stratified analysis. The results demonstrated that worse prognosis was observed in the above subgroups among the patients who carried 3 to 4 unfavorable loci. The cumulative effects of SNPs may further impact the expression of survivin and result in obvious observations in the subgroups.
Furthermore, Cox regression analysis showed that the genotype GG of rs8073069 was consistently correlated with NSCLC prognosis in both the total study subjects and the subgroup patients with only chemotherapy (HR ϭ 1.80, p ϭ 0.008; HR ϭ 2.18, p ϭ 0.021, respectively). Studies suggested that survivin plays a role in tumor progression and chemoresistance by inhibiting cell death induced by several anticancer agents, including paclitaxel, etoposide, and tumor necrosis factor-a-related apoptosis-inducing ligand. 38 -41 In vitro and in vivo studies showed that inhibiting survivin may reduce tumor growth potential and sensitizes tumor cells to chemotherapeutic agents, such as paclitaxel, cisplatin, etoposide, gamma irradiation, and immunotherapy. 42 Biran et al. 43 found that by blocking the expression of survivin, combination therapy with valproic acid (VPA) and farnesylthiosalicylic acid might offer a promising therapeutic approach to the treatment of epithelial tumors. Recently, two reviews about anticancer therapy summarized that survivin had been proposed as an attractive target for new anticancer interventions and would play an important role for survivin-targeted cancer therapy in the future clinical application. 44, 45 Although a few previous case-control studies focused on the association between survivin rs9904341 (-31GϾC) and the susceptibility of cancer, [12] [13] [14] [15] no significant association of rs9904341 with lung caner prognosis was observed in this study population. A possible explanation for the discrepancy may be the different mechanism in terms of lung cancer susceptibility and prognosis. Moreover, the significant polymorphism rs8073069 was in linkage disequilibrium with rs9904341 (D' ϭ 1.0 and R 2 ϭ 0.404) in our subjects, suggesting that the role of rs9904341 may be represented partially by rs8073069. Further functional studies are warranted to elucidate the biologic significance of these two SNPs.
In conclusion, our findings suggest that polymorphisms in survivin may be a genetic modifier for NSCLC prognosis in this Chinese population, especially for the promoter SNPs among patients after chemotherapy. However, further expression or functional studies are warranted to clarify the role of survivin gene as a prognostic or targeted biomarker for NSCLC patients.
